Document Detail

Prostaglandin E1 decreases human arterial accumulation of radiolabeled apo B-containing lipoproteins in vivo.
MedLine Citation:
PMID:  9218925     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: An increased apo B-containing lipoprotein influx and cholesterol ester accumulation in arteries are well-known events in human atherogenesis. In vitro and experimental animal studies have provided evidence of a beneficial effect of PGE1 on both vascular apo B-containing lipoprotein accumulation and cholesterol ester content. METHODS: We examined the effect of PGE1 (administered via an intravenous portable infusion pump at a rate of 5 ng PGE1 kg-1.min-1 for 5 days a week, 6 h daily, over a total of 5 weeks) in ten patients (eight males, two females) on 123I-apo B-containing lipoprotein accumulation into the large arteries in vivo. Apo B-containing lipoprotein isolation was carried out by immunoaffinity chromatography and radiolabeling with the iodine monochloride method. 123I-apo B-containing lipoprotein accumulation was imaged and quantified by means of special computer software before and after 5 weeks of PGE1 therapy. RESULTS: PGE1 led to a significant decrease in maximal arterial apo B-containing lipoprotein retention. The mean decrease in the carotid and femoral arteries in type I lesions amounted to between 16.9% and 30.4%, and in type II lesions between 22.4% and 30.7%, 20 h after injection of radiolabeled apo B-containing lipoprotein. The type of arterial apo B-containing lipoprotein kinetic curves, however, remained unchanged. CONCLUSION: These findings indicate that PGE1 decreases the apo B-containing lipoprotein influx in the large arteries and the vascular cholesterol content, suggesting that PGE1 may lead to regression of lipid-rich lesions in human in vivo.
H Kritz; H Sinzinger; G Lupattelli; I Virgolini; P Fitscha; J O'Grady
Related Documents :
15759815 - Changes in flow-mediated dilatation, cytokines and carotid arterial stenosis during agg...
6133105 - Collagen content of atherosclerotic arteries is higher in smokers than in non-smokers.
10073975 - Extent and composition of coronary lesions in relation to fat distribution in women you...
19856135 - Coronary angiographic studies of impaired glucose regulation and coronary artery diseas...
7573545 - Opioids contribute to hypoxia-induced pial artery dilation through activation of atp-se...
21495825 - Aggressive intervention to treat a young woman with intracranial hemorrhage following u...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  European journal of clinical pharmacology     Volume:  52     ISSN:  0031-6970     ISO Abbreviation:  Eur. J. Clin. Pharmacol.     Publication Date:  1997  
Date Detail:
Created Date:  1997-08-26     Completed Date:  1997-08-26     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  1256165     Medline TA:  Eur J Clin Pharmacol     Country:  GERMANY    
Other Details:
Languages:  eng     Pagination:  191-7     Citation Subset:  IM    
Wilhelm Auerswald Atherosclerosis Research Group (ASF) Vienna, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alprostadil / pharmacology*,  therapeutic use
Apolipoproteins B / metabolism*
Arteriosclerosis / drug therapy*,  metabolism
Carotid Arteries / drug effects,  metabolism
Cholesterol / metabolism
Femoral Artery / drug effects,  metabolism
Infusions, Intravenous
Iodine Radioisotopes
Lipoproteins, LDL / metabolism
Middle Aged
Triglycerides / metabolism
Reg. No./Substance:
0/Apolipoproteins B; 0/Iodine Radioisotopes; 0/Lipoproteins, LDL; 0/Triglycerides; 57-88-5/Cholesterol; 745-65-3/Alprostadil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Drug-induced thrombocytopenia: clinical data on 309 cases and the effect of corticosteroid therapy.
Next Document:  Cytotoxic activity of cyclosporin A and [3-keto-Bmt1]-[Val2]-cyclosporin (SDZ PSC 833) on tumour cel...